Session speakers are among the PBM, specialty pharmacy, pharma and biotech, and affiliated industries’ top thought leaders and decision makers. The conference sessions will be available to watch “On Demand” with two sessions live streaming from 11 am – 12:45 pm ET on September 14 and 15. All sessions will remain available to view for registered attendees on the virtual conference platform through the end of September.

Additionally, new this year we have added a “sessions-only” registration option, which allows anyone to register to view all conference sessions. For more information contact Jenny Bradham.

Monday, September 14
6:00 am - 9:00 pm ET

Virtual Meeting Rooms Open

On Demand Sessions

Welcome Remarks 

JC Scott, President & Chief Executive Officer, PCMA

Brian McCarthy, Chief Strategy and Business Operations Officer, PCMA


The Long Game Strategy for Transforming Pharmacy from Volume to Value  – A Call to Action for all Stakeholders

Chronis Manolis, Senior Vice President, Pharmacy Services & Chief Pharmacy Officer, UPMC Health Plan

View Details

Pharmacy is way behind in the move to value. This session will look at key stakeholders (ie PBMs, payors and pharma) and their leadership role in transforming pharmacy to a value construct.

By attending this session you should be able to:

  • Review one payor’s perspective on the best arrangements for key stakeholders to take a leadership role in transforming pharmacy; and
  • Describe a roadmap to how pharmacy can evolve; and
  • List at least two real-world examples of how pharmacy is still operating under a volume construct.


Drug Pricing Reform Efforts: Administration EOs and Political Dynamics 

Joe Grogan, Former Assistant to President Donald J. Trump and Director of the Domestic Policy Council

Moderator: Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips LLP

View Details

Last month, President Trump signed four drug pricing executive orders (EO’s). These EO’s direct agency action across a host of policy areas, including Part D rebates, Part B reimbursement and pricing, 340B drug discounts, and drug importation. Since the introduction of the Administration EO’s, it has been unclear which specific policies will be advanced or finalized.

During this session Joe will share insights and projections about the pandemic, EOs, including the rebate rule, prescription drug pricing and more.

LIVE STREAM Sessions 11:00 am - 12:45 pm ET

11:00 am – 11:45 am ET

PBM Industry Priorities (live streaming)

Alan Lotvin, Executive Vice President, CVS Health & President, CVS Caremark

Ken Paulus. President & Chief Executive Officer, Prime Therapeutics

Moderator: JC Scott, President & Chief Executive Officer, PCMA

View Details

PCMA leadership will engage in a dialog covering the most pressing matters of the day including; PBM’s role in confronting the COVID-19 pandemic, aligning the patient centric business objectives of all supply chain partners, and the importance of collaboration between the PBM and biopharmaceutical industries.


12:00 pm – 12:45 pm ET

Tracking New Realities Brought on in 2020 (live streaming)

Kabir Nath, President & CEO, Otsuka North America Pharmaceutical Business

William Fleming, President, Clinical and Pharmacy Solutions, Healthcare Services, Humana Inc.

Moderator: Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips LLP

View Details

2020 has been a year of unexpected challenges for everyone, especially those delivering health care. There have been three major crisis going on all at the same time – the pandemic, social disparities, and economic unevenness – that has impacted business. Join us as two industry leader’s share their perspectives on the social justice reform, the “new normal” for the healthcare supply chain, changes in behavior health prevalence, as well diagnosis and treatment in the COVID-19 era.


Tuesday, September 15
6:00 am - 9:00 pm ET

Virtual Meeting Rooms Open

On Demand Sessions

Trends, Issues & Outlook during COVID-19

Doug Long, Vice President, Industry Relations, IQVIA

View Details

This session will explore trends impacting the U.S. pharmaceutical market during COVID-19.

Topics addressed will include:

  • Prescription Demand
    • Specialty vs. Traditional
    • Acute vs. Chronic
    • New vs. Refill
    • 30 day vs. 90 day
    • Mail vs. Retail
  • Telehealth Impact, Elective Surgery and Procedure Backlogs
  • Method of Payment Shifts
  • Latest News on Vaccines


Encouraging a Robust US Biosimilars Marketplace: What’s Best for Payers, Patients and Drug Makers?

Sheila Frame, Vice President, Marketing, Market Access and Patient Services, Sandoz

Mike Zeglinski, Senior Vice President & Chief Executive Officer, Optum Specialty & Infusion Pharmacies, OptumRx

Moderator: Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips LLP

View Details

When we think about rising prescription drug costs, we need to think about biologic drugs. In recent years, startling breakthrough have come to market that give hope to millions who, until now, had no effective treatments for their conditions. At the same time, some of these treatments have arrived with very high prices. The creation of a U.S. pathway for biosimilar drug approval in the Affordable Care Act came with great hopes for bringing competition and savings to the biologic drug market.

This panel will discuss where the biosimilar market is and where we are headed. Topics covered in this session will include proposals and incentives to encourage the uptake of biosimilars, reimbursement rates, aspects impacting adoption, and interchangeability.


The Path Forward for Medication Access and Patient-Centered Care (session Sponsored by CoverMyMeds)

Kyle Grimslid, Director, Clinical Solutions, CoverMyMeds

View Details

Topics addressed will include:

  • With more patients than ever on high deductible plans, many are exposed to the full cost of their medications for much of the year. Prescription price transparency tools can help improve patient adherence by showing more possible avenues of medication affordability.
  • Specialty medications are among the most complex and difficult for patients to access, afford and adhere to. While specialty support services are sometimes available to help patients, their impact is dampened by low awareness and manual workflows.
  • The COVID-19 pandemic has impacted how patients afford and access their medications – but it’s also cemented technology’s role as a change agent in breaking down barriers to therapy.


Learning objectives:

  • Review major medication access barriers for patients.
  • Identify how technology can benefit patients and providers in prescription decision support as we move forward in healthcare.

Describe how COVID-19 has further impacted patients with chronic conditions who are prescribed specialty therapies

LIVE STREAM Sessions 11:00 am - 12:45 pm ET

11:00 am – 11:45 am ET

Drug Price and Affordability Challenges: Market Solutions and Efforts in Washington (live streaming)

Amy Bricker, Senior Vice President, Supply Chain and Drug Procurement, Express Scripts

Kent Rogers, Senior Vice President, Chief Formulary & Procurement Officer, Industry Relations, UnitedHealth Group

Moderator: Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips LLP

View Details

Two of the PBM industry’s top thought leaders and influencers will engage in a discussion on the evolving and dynamic role PBMs play in the drug supply chain as it relates to prescription drug access, affordability, and outcomes.


12:00 pm – 12:45 pm ET

Evolving Policy and Business Dynamics of 2020 and 2021 (live streaming)

Kate Larkin, Senior Vice President and Head, U.S. Value, Access and Payment, Bristol-Myers Squibb

Jamey Millar, Senior Vice President, Managed Markets and Government Affairs, GlaxoSmithKline

Moderator: Ian Spatz, Senior Advisor, Manatt Health, Manatt, Phelps & Phillips LLP

View Details

Two of the biopharmaceutical industry’s top thought leaders and influencers will engage in a discussion on recent policy proposals to address drug affordability and price, alignment opportunities between drug makers, payers, and PBMs, patient affordability and access, and other dynamics impacting the drug supply chain.

3:00 pm - 4:00 pm ET

PCMA Diversity & Inclusion Initiative Event

View Details

Join us for a presentation and discussion that examines current events – the pandemic, economic crisis and social unrest – through the lens of diversity and inclusion and their impact on us as individuals and as an industry.  What opportunities do an increasingly diverse workforce, workplace and marketplace bring to our industry? What can we do to be more inclusive?

For more than 25 years, Janet Crenshaw Smith, Founder and President of Ivy Planning Group, has worked with the world’s largest organizations to build and execute diversity and inclusion strategies. She has seen what works and what doesn’t. She will share lessons learned and provide authentic advice, evidence-based solutions, and real-world tested approaches to leveraging diversity and inclusion as an opportunity.

Following Janet’s remarks, a panel from our industry will share their personal perspectives and experiences on diversity and inclusion. The panel will speak for about 30 minutes.


Opening Remarks by 2020 Co-Chairs

Bethanie Stein, Vice President, Supply Chain & Analytics, Humana

Christine Marsh, Senior Vice President, Market Access, Boehringer Ingelheim


Diversity, Equity and Inclusion 2020: Opportunities, Lessons Learned and Strategies for Success 

Janet Smith, President, Ivy Planning Group


Panel Discussion

Jonah Houts, Vice President & General Manager, Network Contracting and Strategy, Express Scripts

Lilian Ndehi, Director Patient Safety & Pharmacy Stars, Humana

Tina Patel, Vice President, Market Access Marketing, Boehringer Ingelheim

Moderator: Janet Smith, President, Ivy Planning Group